Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 4, 2013, Pages 324-325

  Relling, M V ^a   Gardner, E E ^b   Sandborn, W J ^c   Schmiegelow, K ^d,e   Pui, C H ^a   Yee, S W ^f   Stein, C M ^g   Carrillo, M ^h   Evans, W E ^a   Hicks, J K ^a   Schwab, M ^i,j   Klein, T E ^h  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CHILDHOOD DISEASE; ENTERITIS; GENOTYPE; HUMAN; KNOWLEDGE BASE; LABORATORY TEST; LIBRARY SCIENCE; MEDICAL LITERATURE; NOMENCLATURE; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RECOMMENDED DRUG DOSE;

6-MERCAPTOPURINE; ANTIMETABOLITES; AZATHIOPRINE; GENOTYPE; GUIDELINES AS TOPIC; HUMANS; METHYLTRANSFERASES;

EID: 84875438476     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.4     Document Type: Article

References (5)

1. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
2. Relling, M.V. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391 (2011).
3. Krynetski, E. & Evans, W.E. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22, 7403-7413 (2003).
4. González-Lama, Y. et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment. Pharmacol. Ther. 34, 544-554 (2011).
5. Adam de Beaumais, T. et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 71, 575-584 (2011).